{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:35:32Z","timestamp":1787841332052,"version":"build-2784847793"},"reference-count":76,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,5,6]],"date-time":"2017-05-06T00:00:00Z","timestamp":1494028800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,10]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) are at increased risk of invasive fungal infections, especially during the early neutropenic phase and severe graft- versus-host disease. Mold-active prophylaxis should be limited to the highest risk groups. Empiric antifungal therapy for HSCT with persistent febrile neutropenia is associated with unacceptable response rates, unnecessary antifungal therapy, increased risk of toxicity, and inflated costs. Empiric therapy should not be a substitute for detailed work up to identify the cause of fever in such patients. The improved diagnostic performance of serum biomarkers such as galac- tomannan and \u03b2-D-glucan, as well as polymerase chain reaction assays has allowed the development of diagnostic-driven antifungal therapy strategies for high risk patients. Diagnostic-driven approaches have resulted in reduced unnecessary antifungal exposure, improved diagnosis of invasive fungal disease, and reduced costs without increased risk of mortality. The appropriateness of diagnostic-driven antifungal strategy for individual HSCT centers depends on the availability and turnaround times for diagnostics, multidisciplinary expertise, and the local epidemiology of invasive fungal infections. Echinocandins are the treatment of choice for invasive candidiasis in most HSCT recipients. Fluconazole may be used for the treatment of invasive candidiasis in hemodynamically stable patients with no prior azole exposure. The primary treatment of choice for invasive aspergillosis is voriconazole. Alternatives include isavuconazole and lipid formulations of amphotericin. Currently available evidence does not support routine primary combination antifungal therapy for invasive aspergillosis. However, combination salvage antifungal therapy may be considered in selected patients. Therapeutic drug monitoring is recommended for the majority of HSCT recipients on itraconazole, posaconazole, or voriconazole.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1016\/j.hemonc.2017.05.013","type":"journal-article","created":{"date-parts":[[2017,6,13]],"date-time":"2017-06-13T23:31:29Z","timestamp":1497396689000},"page":"239-244","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":25,"title":["Complications of hematopoietic stem transplantation"],"prefix":"10.4103","volume":"10","author":[{"given":"Ali S.","family":"Omrani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reem S.","family":"Almaghrabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"10.1016\/j.hemonc.2017.05.013_b0005","first-page":"002","article-title":"Infectious complications of hematopoietic stem cell transplantation","volume":"S3","author":"Kedia","year":"2013","journal-title":"J Stem Cell Res Ther"},{"key":"10.1016\/j.hemonc.2017.05.013_b0010","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.idc.2010.01.010","article-title":"Hematopoietic stem cell transplantation: an overview of infection risks and epidemiology","volume":"24","author":"Wingard","year":"2010","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.hemonc.2017.05.013_b0015","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1086\/591969","article-title":"Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation","volume":"47","author":"Garcia-Vidal","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.hemonc.2017.05.013_b0020","doi-asserted-by":"crossref","first-page":"4358","DOI":"10.1182\/blood-2002-05-1496","article-title":"Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors","volume":"100","author":"Marr","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.05.013_b0025","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1086\/651263","article-title":"Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001\u20132006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database","volume":"50","author":"Kontoyiannis","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.hemonc.2017.05.013_b0030","first-page":"1068","article-title":"The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study","volume":"91","author":"Pagano","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.hemonc.2017.05.013_b0035","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.2146\/ajhp080325","article-title":"Mortality, length of hospitalization, and costs associated with invasive fungal infections in high-risk patients","volume":"66","author":"Menzin","year":"2009","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.hemonc.2017.05.013_b0040","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1086\/595846","article-title":"Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry","volume":"48","author":"Neofytos","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.hemonc.2017.05.013_b0045","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1038\/bjc.2012.147","article-title":"Mould-active compared with fluconazole prophylaxis to prevent invasive fungal diseases in cancer patients receiving chemotherapy or haematopoietic stem-cell transplantation: a systematic review and meta-analysis of randomised controlled trials","volume":"106","author":"Ethier","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.hemonc.2017.05.013_b0050","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/j.1365-2141.2011.08650.x","article-title":"Antifungal prophylaxis during treatment for haematological malignancies: are we there yet?","volume":"153","author":"Rogers","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hemonc.2017.05.013_b0055","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/bmt.2010.175","article-title":"European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3\u20132009 update","volume":"46","author":"Maertens","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.hemonc.2017.05.013_b0060","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1007\/s00277-016-2711-1","article-title":"Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016","volume":"95","author":"Ullmann","year":"2016","journal-title":"Ann Hematol"},{"key":"10.1016\/j.hemonc.2017.05.013_b0065","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1111\/imj.12595","article-title":"Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2014","volume":"44","author":"Fleming","year":"2014","journal-title":"Int Med J"},{"issue":"Suppl. 7","key":"10.1016\/j.hemonc.2017.05.013_b0070","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/1469-0691.12041","article-title":"ESCMID guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT)","volume":"18","author":"Ullmann","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.hemonc.2017.05.013_b0075","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1182\/blood.V96.6.2055","article-title":"Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial","volume":"96","author":"Marr","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.05.013_b0080","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1182\/blood-2003-08-2644","article-title":"Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants","volume":"103","author":"Marr","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.05.013_b0085","doi-asserted-by":"crossref","first-page":"5111","DOI":"10.1182\/blood-2010-02-268151","article-title":"Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation","volume":"116","author":"Wingard","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.05.013_b0090","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1086\/422312","article-title":"Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation","volume":"39","author":"van Burik","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.hemonc.2017.05.013_b0095","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ijantimicag.2007.10.001","article-title":"Safety of a weekly high dose of liposomal amphotericin B for prophylaxis of invasive fungal infection in immunocompromised patients: PROPHYSOME Study","volume":"31","author":"Cordonnier","year":"2008","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.hemonc.2017.05.013_b0100","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/sj.bmt.1705592","article-title":"High-dose weekly liposomal amphotericin B antifungal prophylaxis following reduced-intensity conditioning allogeneic stem cell transplantation","volume":"39","author":"El-Cheikh","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.hemonc.2017.05.013_b0105","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1086\/586739","article-title":"Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial","volume":"46","author":"Rijnders","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.hemonc.2017.05.013_b0110","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/bmt.2010.185","article-title":"Clinical efficacy and safety of primary antifungal prophylaxis with posaconazole vs itraconazole in allogeneic blood and marrow transplantation","volume":"46","author":"Sanchez-Ortega","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.hemonc.2017.05.013_b0115","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.bbmt.2010.04.017","article-title":"Efficacy, safety, and breakthrough infections associated with standard long-term posaconazole antifungal prophylaxis in allogeneic stem cell transplantation recipients","volume":"17","author":"Winston","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.hemonc.2017.05.013_b0120","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/bmt.2009.210","article-title":"Voriconazole provides effective prophylaxis for invasive fungal infection in patients receiving glucocorticoid therapy for GVHD","volume":"45","author":"Gergis","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.hemonc.2017.05.013_b0125","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.hemonc.2017.05.013_b0130","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3324\/haematol.2012.061952","article-title":"The role of antifungal treatment in hematology","volume":"97","author":"Maertens","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.hemonc.2017.05.013_b0135","first-page":"668","article-title":"EORTC International Antimicrobial Therapy Cooperative Group","volume":"86","author":"Empiric antifungal therapy in febrile granulocytopenic patients","year":"1989","journal-title":"Am J Med"},{"key":"10.1016\/j.hemonc.2017.05.013_b0140","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0002-9343(82)90594-0","article-title":"Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia","volume":"72","author":"Pizzo","year":"1982","journal-title":"Am J Med"},{"key":"10.1016\/j.hemonc.2017.05.013_b0145","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/0959-8049(95)00619-2","article-title":"Fluconazole versus amphotericin B as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients: a pragmatic, multicentre, prospective and randomised clinical trial","volume":"32a","author":"Viscoli","year":"1996","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.hemonc.2017.05.013_b0150","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S0002-9343(99)00457-X","article-title":"A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer","volume":"108","author":"Winston","year":"2000","journal-title":"Am J Med"},{"key":"10.1016\/j.hemonc.2017.05.013_b0155","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1056\/NEJM199903113401004","article-title":"Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia","volume":"340","author":"Walsh","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hemonc.2017.05.013_b0160","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJM200201243460403","article-title":"Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever","volume":"346","author":"Walsh","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hemonc.2017.05.013_b0165","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1056\/NEJMoa040446","article-title":"Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia","volume":"351","author":"Walsh","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hemonc.2017.05.013_b0170","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1093\/cid\/cir073","article-title":"Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America","volume":"52","author":"Freifeld","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.hemonc.2017.05.013_b0175","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1177\/2040620716656381","article-title":"Recent developments in the management of invasive fungal infections in patients with oncohematological diseases","volume":"7","author":"Ruhnke","year":"2016","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.hemonc.2017.05.013_b0180","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1473-3099(13)70076-8","article-title":"Galactomannan and PCR versus culture and histology for directing use of antifungal treatment for invasive aspergillosis in high-risk haematology patients: a randomised controlled trial","volume":"13","author":"Morrissey","year":"2013","journal-title":"Lancet Infect Dis"},{"issue":"Suppl. 1","key":"10.1016\/j.hemonc.2017.05.013_b0185","doi-asserted-by":"crossref","first-page":"i37","DOI":"10.1093\/jac\/dkq440","article-title":"Treatment and timing in invasive mould disease","volume":"66","author":"Maertens","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.hemonc.2017.05.013_b0190","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/hon.2031","article-title":"A hematology consensus agreement on antifungal strategies for neutropenic patients with hematological malignancies and stem cell transplant recipients","volume":"31","author":"Girmenia","year":"2013","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.hemonc.2017.05.013_b0195","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1086\/509917","article-title":"Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign","volume":"44","author":"Greene","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.hemonc.2017.05.013_b0200","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1093\/cid\/civ555","article-title":"Galactomannan and polymerase chain reaction-based screening for invasive aspergillosis among high-risk hematology patients: a diagnostic meta-analysis","volume":"61","author":"Arvanitis","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.hemonc.2017.05.013_b0205","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/bmt.2011.178","article-title":"ECIL recommendations for the use of biological markers for the diagnosis of invasive fungal diseases in leukemic patients and hematopoietic SCT recipients","volume":"47","author":"Marchetti","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.hemonc.2017.05.013_b0210","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S1473-3099(15)70006-X","article-title":"British Society for Medical Mycology best practice recommendations for the diagnosis of serious fungal diseases","volume":"15","author":"Schelenz","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.hemonc.2017.05.013_b0215","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1086\/597395","article-title":"Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial","volume":"48","author":"Cordonnier","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.hemonc.2017.05.013_b0220","doi-asserted-by":"crossref","first-page":"e0140930","DOI":"10.1371\/journal.pone.0140930","article-title":"Meta-analysis and cost comparison of empirical versus pre-emptive antifungal strategies in hematologic malignancy patients with high-risk febrile neutropenia","volume":"10","author":"Fung","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.hemonc.2017.05.013_b0225","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/cid\/ciu833","article-title":"Serum galactomannan versus a combination of galactomannan and polymerase chain reaction-based Aspergillus DNA detection for early therapy of invasive aspergillosis in high-risk hematological patients: a randomized controlled trial","volume":"60","author":"Aguado","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"1317\u201328","key":"10.1016\/j.hemonc.2017.05.013_b0230","first-page":"e2","article-title":"Economic comparison of an empirical versus diagnostic-driven strategy for treating invasive fungal disease in immunocompromised patients","volume":"37","author":"Barnes","year":"2015","journal-title":"Clin Ther"},{"key":"10.1016\/j.hemonc.2017.05.013_b0235","doi-asserted-by":"crossref","first-page":"4664","DOI":"10.1128\/AAC.00723-13","article-title":"Cost-effectiveness analysis comparing two approaches for empirical antifungal therapy in hematological patients with persistent febrile neutropenia","volume":"57","author":"Mart\u00edn-Pe\u00f1a","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.hemonc.2017.05.013_b0240","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1111\/imj.12596","article-title":"Consensus guidelines for the use of empiric and diagnostic-driven antifungal treatment strategies in haematological malignancy, 2014","volume":"44","author":"Morrissey","year":"2014","journal-title":"Int Med J"},{"issue":"Suppl. 1","key":"10.1016\/j.hemonc.2017.05.013_b0245","doi-asserted-by":"crossref","first-page":"i45","DOI":"10.1093\/jac\/dkq441","article-title":"Optimizing management of invasive mould diseases","volume":"66","author":"Agrawal","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.hemonc.2017.05.013_b0250","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/civ1194","article-title":"Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.hemonc.2017.05.013_b0255","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3324\/haematol.2016.152900","article-title":"ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients","volume":"102","author":"Tissot","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.hemonc.2017.05.013_b0260","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1093\/cid\/cis021","article-title":"Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials","volume":"54","author":"Andes","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.hemonc.2017.05.013_b0265","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1111\/imj.12597","article-title":"Consensus guidelines for the treatment of yeast infections in the haematology, oncology and intensive care setting, 2014","volume":"44","author":"Chen","year":"2014","journal-title":"Int Med J"},{"key":"10.1016\/j.hemonc.2017.05.013_b0270","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole versus amphotericin b for primary therapy of invasive aspergillosis","volume":"347","author":"Herbrecht","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hemonc.2017.05.013_b0275","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1086\/510592","article-title":"Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality","volume":"44","author":"Upton","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.hemonc.2017.05.013_b0280","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.hemonc.2017.05.013_b0285","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1111\/imj.12598","article-title":"Consensus guidelines for the treatment of invasive mould infections in haematological malignancy and haemopoietic stem cell transplantation, 2014","volume":"44","author":"Blyth","year":"2014","journal-title":"Int Med J"},{"key":"10.1016\/j.hemonc.2017.05.013_b0290","doi-asserted-by":"crossref","first-page":"81","DOI":"10.7326\/M13-2508","article-title":"Combination antifungal therapy for invasive aspergillosis: a randomized trial","volume":"162","author":"Marr","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.hemonc.2017.05.013_b0295","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ijid.2014.07.007","article-title":"Salvage combination antifungal therapy for acute invasive aspergillosis may improve outcomes: a systematic review and meta-analysis","volume":"28","author":"Panackal","year":"2014","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.hemonc.2017.05.013_b0300","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ijantimicag.2014.08.012","article-title":"Clinical experience of the use of voriconazole, caspofungin or the combination in primary and salvage therapy of invasive aspergillosis in haematological malignancies","volume":"45","author":"Raad","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.hemonc.2017.05.013_b0305","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.idc.2015.10.011","article-title":"Mucormycoses","volume":"30","author":"Farmakiotis","year":"2016","journal-title":"Infect Dis Clin North Am"},{"issue":"Suppl. 3","key":"10.1016\/j.hemonc.2017.05.013_b0310","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/1469-0691.12371","article-title":"ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013","volume":"20","author":"Cornely","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.hemonc.2017.05.013_b0315","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/S1473-3099(16)00071-2","article-title":"Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis","volume":"16","author":"Marty","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.hemonc.2017.05.013_b0320","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.ijantimicag.2011.05.010","article-title":"Posaconazole for the treatment of mucormycosis","volume":"38","author":"Enoch","year":"2011","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.hemonc.2017.05.013_b0325","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/MJT.0b013e3181ff7e10","article-title":"Importance of pharmacokinetic considerations for selecting therapy in the treatment of invasive fungal infections","volume":"19","author":"Lewis","year":"2012","journal-title":"Am J Ther"},{"key":"10.1016\/j.hemonc.2017.05.013_b0330","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1086\/524669","article-title":"Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes","volume":"46","author":"Pascual","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.hemonc.2017.05.013_b0335","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.clpt.2004.02.002","article-title":"Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status","volume":"75","author":"Ikeda","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.hemonc.2017.05.013_b0340","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/sj.bmt.1705754","article-title":"Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole","volume":"40","author":"Trifilio","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.hemonc.2017.05.013_b0345","doi-asserted-by":"crossref","first-page":"4782","DOI":"10.1128\/AAC.01083-10","article-title":"Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients","volume":"55","author":"Troke","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.hemonc.2017.05.013_b0350","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ijantimicag.2012.02.002","article-title":"Posaconazole plasma concentrations and invasive mould infections in patients with haematological malignancies","volume":"39","author":"Hoenigl","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.hemonc.2017.05.013_b0355","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1046\/j.1439-0507.1999.00505.x","article-title":"Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole","volume":"42","author":"Glasmacher","year":"1999","journal-title":"Mycoses"},{"key":"10.1016\/j.hemonc.2017.05.013_b0360","doi-asserted-by":"crossref","first-page":"e753","DOI":"10.1016\/j.ijid.2011.06.004","article-title":"Voriconazole-related severe adverse events: clinical application of therapeutic drug monitoring in Korean patients","volume":"15","author":"Kim","year":"2011","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.hemonc.2017.05.013_b0365","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/cid\/cis599","article-title":"The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial","volume":"55","author":"Park","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.hemonc.2017.05.013_b0370","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/jac\/dkt508","article-title":"Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology","volume":"69","author":"Ashbee","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.hemonc.2017.05.013_b0375","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1111\/imj.12600","article-title":"Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014","volume":"44","author":"Chau","year":"2014","journal-title":"Int Med J"},{"key":"10.1016\/j.hemonc.2017.05.013_b0380","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1155\/2014\/340586","article-title":"Therapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspective","volume":"25","author":"Laverdiere","year":"2014","journal-title":"Can J Infect Dis Med Microbiol"}],"container-title":["Hematology\/Oncology and Stem Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1658387617300493?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1658387617300493?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ovid.com\/02275670-201710040-00014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:50:13Z","timestamp":1787838613000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/02275670-201710040-00014"}},"subtitle":["Fungal infections"],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":76,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1016\/j.hemonc.2017.05.013","relation":{},"ISSN":["1658-3876"],"issn-type":[{"value":"1658-3876","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]}}}